Amebic dysentery

Summary

Amebic dysentery (MONDO:0024275) is a disease and 5 clinical trials. Top therapeutic interventions include auranofin. A subtype of protozoal dysentery — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	amebic dysentery
Mondo ID	MONDO:0024275
MeSH	D004404
NCIT	C34558
UMLS	C0013370
MedGen	8512
Is cancer (heuristic)	no

Also known as: Amebiases, intestinal · amebiasis, intestinal · amebic colitides · amebic colitis · amebic dysenteries · amebic dysentery · amoebiases, intestinal · amoebiasis due to Entamoeba histolytica · amoebiasis, intestinal · amoebic Colitides · amoebic colitis · amoebic dysenteries · amoebic dysentery · amoebic dysentery due to Entamoeba histolytica · Colitides, amebic · Colitides, amoebic · colitis, amebic · colitis, amoebic · dysenteries, amebic · dysenteries, amoebic (+9 more)

Disease family

This is a subtype of protozoal dysentery. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › gastrointestinal mucositis › inflammatory diarrhea › dysentery › protozoal dysentery › amebic dysentery

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02736968	PHASE2	COMPLETED	Auranofin for Giardia Protozoa
NCT02680665	Not specified	COMPLETED	Ameparomo Capsules 250 mg Drug Use Investigation
NCT03262025	Not specified	COMPLETED	Primary Cecal Pathologies Presenting as Acute Abdomen
NCT03491228	Not specified	COMPLETED	Anaemetro I.V. Infusion 500mg Drug Use Investigation
NCT04759937	Not specified	UNKNOWN	Immunochromatography Versus Microscopy for Diagnosis of Entamoeba Histolytica/Dispar Infection.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
AURANOFIN	4	1
CHEMBL3774645	0	1
CHEMBL4303702	0	1
CHEMBL5279950	0	1